Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, announced the advancement of its ARYA-3 clinical trial to Phase...
Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq plus Avastin demonstrated a statistically significant...
